Sponsored by
This may be the most important article of the year. It is the report on the phase 3 clinical trial for newly diagnosed GBM trial comparing Optune and the standard of care vs the standard of care alone. Excellent results - best of any large phase 3 GBM trial. Better than the results that made Temodar the standard of care. The trial was stopped early by the FDA when they saw the Optune group did so much better than the control group, and they allowed the control group to cross over into the treatment group. This is the first time (that I am aware of) this happened for brain tumors! Hopefully this will remove all doubt that Optune works and should be included in the standard of care for newly diagnosed gbm.
click the link above for the full article!